

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Ocumention Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
OT-502 APPROVED FOR URGENT MEDICAL NEEDS IN HAINAN

This announcement is made by Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Hainan Medical Product Administration has granted approval to the Group’s product, OT-502 (DEXYCU®), allowing it to be imported as foreign drugs not yet approved in China for urgent medical needs in Boao Lecheng International Medical Tourism Pilot Zone (博鳌樂城醫療旅遊先行區) in Hainan Province, China, which may potentially accelerate the new drug application submission of OT-502 in China.

OT-502 (DEXYCU®) is a single-dose, sustained-release solution of dexamethasone, a corticosteroid, for the treatment of postoperative inflammation. As of the date of this announcement, DEXYCU® is the first and only single-dose, sustained-release intracameral steroid for the treatment of postoperative inflammation that was approved by the United States Food and Drug Administration. The Group is developing OT-502 as a potential first-in-class treatment for postoperative inflammation associated with cataract surgery in China.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize OT-502 (DEXYCU®) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumention Therapeutics
Dr. Lian Yong CHEN
Chairman and Executive Director

Hong Kong, July 7, 2021

As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.